Magnolia Medical Technologies makes a product that aims to reduce the rate of false positive diagnoses of sepsis.

Share story

Seattle-based Magnolia Medical Technologies has raised $13.8 million to continue developing a product that aims to provide accurate blood tests.

Magnolia makes the SteriPath blood-collection system, which is meant to decrease the number of false positives for sepsis, a complication of a bloodstream infection that is often treated with antibiotics and can be life-threatening.

Such false positives can mean that patients are given procedures and treatments they don’t need, exposing them to more risk, Magnolia said in a news release announcing the funding. More than 1 million people in the U.S. are misdiagnosed with sepsis each year, the company said.

Menlo Park, Calif.-based HealthQuest Capital led the funding round and announced managing partner Garheng Kong would join Magnolia’s board.

SteriPath is commercially available, and the company will use the investment to expand the product into hospitals.